Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs

Kim, T. W., Lebkowska-Wieruszewska, B., Owen, H., Yun, H. I., Kowalski, C. J. and Giorgi, M. (2014) Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs. The Veterinary Journal, 200 1: 77-81. doi:10.1016/j.tvjl.2013.12.020


Author Kim, T. W.
Lebkowska-Wieruszewska, B.
Owen, H.
Yun, H. I.
Kowalski, C. J.
Giorgi, M.
Title Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs
Journal name The Veterinary Journal   Check publisher's open access policy
ISSN 1532-2971
1090-0233
Publication date 2014-04
Year available 2013
Sub-type Article (original research)
DOI 10.1016/j.tvjl.2013.12.020
Open Access Status
Volume 200
Issue 1
Start page 77
End page 81
Total pages 5
Place of publication London, United Kingdom
Publisher Elsevier
Collection year 2014
Language eng
Formatted abstract
Cimicoxib (CX) is a novel imidazole derivative that is a cyclo-oxygenase (COX)-2 selective non-steroidal anti-inflammatory drug and the latest COX-2 selective inhibitor to be released for veterinary use. Currently there is limited information available on the pharmacokinetic (PK) properties of CX. The aim of the current study was to evaluate the PK features of CX after administration of the recommended dose and after administration of a more variable dose rate in the form of the commercially available tablet. In addition, the effects of food intake on the PK properties were also evaluated. In the first study, five healthy Beagle dogs received 2 mg/kg CX via the oral route following a period of fasting. The second study was conducted using six healthy Labrador retriever dogs which each received an 80 mg tablet (approximate dose 1.95–2.5 mg/kg) using a crossover design, both in the fasted and fed condition. The plasma concentrations of CX were detected by a validated HPLC method.

No adverse effects were observed in any dogs during the experiment. The results from the PK analysis were similar between the studies, regardless of precision of dose and fasted and fed conditions. The mean peak concentration of CX was 0.49 and 0.43 μg/mL under fasted and fed conditions, respectively. The mean half-life was about 3 h after all treatments. In addition, simulated multiple dosing data revealed that time over minimal effective concentration was similar after 1.95, 2.0 and 2.5 mg/kg dose administrations. These findings suggest that slight variation from the recommended dose should not alter the therapeutic outcome. In addition, CX can be administered to fed dogs without significantly affecting blood levels.
Keyword Cimicoxib
COX-2 inhibitor
Fasted
Fed
Pharmacokinetics
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Veterinary Science Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 06 May 2014, 01:50:54 EST by System User on behalf of School of Veterinary Science